SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

Search

Valneva SE

Open

3.21 0.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.09

Max

3.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-28M

-37M

Verkoop

7.1M

53M

EPS

-0.25

Winstmarge

-69.865

Werknemers

713

EBITDA

-19M

-26M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+78.13% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-64M

513M

Vorige openingsprijs

2.9

Vorige sluitingsprijs

3.21

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Valneva SE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 nov 2024, 10:28 UTC

Belangrijke Marktbewegers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

3 sep 2024, 10:28 UTC

Winsten

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

15 nov 2024, 10:34 UTC

Marktinformatie

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

3 sep 2024, 10:31 UTC

Marktinformatie

Valneva Shares Gain on Positive Vaccine News -- Market Talk

Peer Vergelijking

Prijswijziging

Valneva SE Prognose

Koersdoel

By TipRanks

78.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.7 EUR  78.13%

Hoogste 8.1 EUR

Laagste 3.3 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Valneva SE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

3.2 / 3.32Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.